نتائج البحث - Janet L. Karlix

  • يعرض 1 - 5 نتائج من 5
تنقيح النتائج
  1. 1
    Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study

    Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study حسب Barry D. Kahan, Janet L. Karlix, Ronald M. Ferguson, Alan B. Leichtman, Shamkant Mulgaonkar, Thomas A. Gonwa, Andrej Skerjanec, Robert Schmouder, Lawrence Chodoff

    منشور في 2003
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    OBESITY DOES NOT PORTEND A BAD OUTCOME FOR KIDNEY TRANSPLANT RECIPIENTS

    OBESITY DOES NOT PORTEND A BAD OUTCOME FOR KIDNEY TRANSPLANT RECIPIENTS حسب Richard J. Howard, Van B. Thai, Pamela R. Patton, Alan W. Hemming, Alan Reed, Willem J. Van der Werf, Shiro Fujita, Janet L. Karlix, Juan C. Scornik

    منشور في 2002
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer

    A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer حسب Gerald S. Falchook, James A. Reeves, Sunil Gandhi, David R. Spigel, Edward Arrowsmith, Daniel J. George, Janet L. Karlix, Gayle P. Pouliot, Maureen M. Hattersley, Eric T. Gangl, Gareth D. James, Jeff Thompson, Deanna L. Russell, Bhavickumar Patel, Rakesh Kumar, Emerson A. Lim

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

    First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma حسب Erika Hamilton, Judy S. Wang, Amit M. Oza, Manish R. Patel, Susanna V. Ulahannan, Todd M. Bauer, Janet L. Karlix, Jorge Zerón-Medina, Giulia Fabbri, Paola Marco‐Casanova, Ganesh Moorthy, Maureen M. Hattersley, Gillian M. Littlewood, Patrick D. Mitchell, Jamal Saeh, Gayle P. Pouliot, Kathleen N. Moore

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors حسب Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer, Charles G. Drake, Jennifer H. Choe, Daniel J. George, Janet L. Karlix, Susanna V. Ulahannan, Kris F. Sachsenmeier, Deanna L. Russell, Ganesh Moorthy, Ben S. Sidders, Elizabeth A. Pilling, Huifang Chen, Maureen M. Hattersley, Mayukh Das, Rakesh Kumar, Gayle P. Pouliot, Manish R. Patel

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: